Tardive Dyskinesia

New England CEPAC

Tardive dyskinesia is a serious and disabling movement disorder that affects individuals treated with antipsychotic agents for a variety of mental health conditions. Though prevention and treatment primarily focus on stopping or changing the offending antipsychotic agent, for some individuals there are no other effective treatment options, and symptoms can persist after discontinuing or changing antipsychotic therapy.

Interventions of Interest:

  • Valbenazine (Ingrezza®, Neurocrine Biosciences, Inc)
  • Deutetrabenazine (Austedo®, Teva)
  • Tetrabenazine (Xenazine®)

Date of Review: December 2017

Associated Meetings

The New England CEPAC convened to review ICER's evidence report assessing the clinical effectiveness and value of therapies to treat tardive dyskinesia, a movement disorder related to prolonged use of antipsychotic medications.


Key Dates

Associated Materials

04/21/2017 – 05/12/2017

05/08/2017

05/08/2017

05/08/2017 – 05/26/2017

06/09/2017

07/12/2017

07/12/2017

10/02/2017

10/02/2017

10/02/2017 – 10/30/2017

11/21/2017

11/21/2017

11/21/2017

12/05/2017

12/05/2017

Slide deck used during ICER’s public meeting on December 5, 2017.